These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 7437348)

  • 1. The use of factor IX concentrates in man: a 9-year experience of Scottish concentrates in the South-East of Scotland.
    Prowse CV; Cash JD
    Br J Haematol; 1981 Jan; 47(1):91-104. PubMed ID: 7437348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Substitution therapy with prothrombin complex concentrates in acquired coagulation disorders].
    Fischer M
    Wien Klin Wochenschr; 1983 Feb; 95(3):82-5. PubMed ID: 6858171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disseminated intravascular coagulation in a patient with haemophilia B during factor IX replacement therapy.
    Ohga S; Saito M; Matsukazi A; Kai T; Ueda K
    Br J Haematol; 1993 Jun; 84(2):343-5. PubMed ID: 8398841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ["COAGULANT" FRACTIONS CONTAINING COAGULATION FACTORS ADSORBABLE BY TRICALCIC PHOSPHATE].
    SOULIER JP; BLATRIX C; STEINBUCH M
    Presse Med (1893); 1964 Apr; 72():1223-8. PubMed ID: 14134215
    [No Abstract]   [Full Text] [Related]  

  • 5. Factor IX thrombogenicity: in vivo effects on coagulation activation and a case report of disseminated intravascular coagulation.
    Small M; Lowe GD; Douglas JT; Forbes CD; Prentice CR
    Thromb Haemost; 1982 Aug; 48(1):76-7. PubMed ID: 7135346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Concentrated antihemophilic globulin in the treatment of hemorrhagic syndromes].
    Baklaja F; Cvetković V; Stajić M; Krivokapić L
    Bilt Hematol Transfuz; 1976; 4(3):61-6. PubMed ID: 1008799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical use of factor IX concentrates].
    Nyman D
    Schweiz Med Wochenschr; 1975 Sep; 105(37):1188-90. PubMed ID: 1215901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of coagulation equilibrium at baseline and during factor VIII and factor IX replacement in haemophiliacs.
    Négrier C; Menart C; Attali O; Petit PY; Lienhart A; Dechavanne M; Ingerslev J
    Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S135-41. PubMed ID: 9819045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coagulation factor IX: successful surgical experience with a purified factor IX concentrate.
    Goldsmith JC; Kasper CK; Blatt PM; Gomperts ED; Kessler CM; Thompson AR; Herring SW; Novak PL
    Am J Hematol; 1992 Jul; 40(3):210-5. PubMed ID: 1609775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Markers of hypercoagulability in patients with hemophilia B given repeated, large doses of factor IX concentrates during and after surgery.
    Santagostino E; Mannucci PM; Gringeri A; Tagariello G; Baudo F; Bauer KA; Rosenberg RD
    Thromb Haemost; 1994 Jun; 71(6):737-40. PubMed ID: 7974341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and biological survey of haemophilia A and B patients infused with French heat-treated concentrates.
    Parquet A; Boneu B; Bosser C; Cazenave JP; Dirat G; Gazengel G; Grunebaum L; Sultan Y; Verroust F; Wiesel ML
    Nouv Rev Fr Hematol (1978); 1988; 30(4):205-7. PubMed ID: 3143099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreased helper/suppressor cell ratios after treatment with factor VIII and IX concentrates and fresh frozen plasma.
    Ragni MV; Lewis JH; Spero JA; Bontempo FA; Rabin BS
    Am J Med; 1984 Feb; 76(2):206-10. PubMed ID: 6230009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Substitution treatment of hemophilia a and b.
    Duckert F
    Schweiz Med Wochenschr; 1975 Jun; 105(24):783-4. PubMed ID: 1145162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of haemophilia B with purified Factor IX (PPSB).
    Loeliger EA; Hensen A; Mattern MJ; Veltkamp JJ; Bruning PF; Hemker HC
    Folia Med Neerl; 1967; 10(4):112-25. PubMed ID: 6073947
    [No Abstract]   [Full Text] [Related]  

  • 15. Summary report and recommendations of the task force members and consultants.
    Ménachd ; Roberts HR
    Thromb Diath Haemorrh; 1975 Jun; 33(3):645-7. PubMed ID: 1154320
    [No Abstract]   [Full Text] [Related]  

  • 16. A five year experience of the use of factor IX type DE(I) concentrate for the treatment of Christmas disease of Oxford.
    Lane JL; Rizza CR; Snape TJ
    Br J Haematol; 1975 Aug; 30(4):435-46. PubMed ID: 1201227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of factor-VII-rich prothrombin complex concentrate in liver disease.
    Green G; Dymock IW; Poller L; Thomson JM
    Lancet; 1975 Jun; 1(7920):1311-4. PubMed ID: 49516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Electroimmunoassay of factor IX in patients with liver damage and vitamin K unresponsive coagulation disorder.
    Girolami A; Burul A; Cappellato G; Dal Bo Zanon R
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1979; 106(1):65-71. PubMed ID: 88391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The management of patients with bleeding disorders.
    Wyld PJ; Dawson KP
    N Z Med J; 1984 Feb; 97(750):118-9. PubMed ID: 6424072
    [No Abstract]   [Full Text] [Related]  

  • 20. [Congenital coagulopathies and coagulation factor inhibitors].
    Oldenburg J; Barthels M
    Hamostaseologie; 2008 Dec; 28(5):335-47. PubMed ID: 19132164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.